5436352026-07-012026-09-305436352026-09-305436352026-03-315436352026-04-012026-09-305436352026-07-012026-09-30in-capmkt:OtherExpenses1Member5436352026-04-012026-09-30in-capmkt:OtherExpenses1Member5436352026-09-30OtherNoncurrentFinancialAssetsDomain15436352026-09-30OtherNoncurrentAssetsDomain15436352026-09-30OtherCurrentFinancialAssetsDomain15436352026-09-30OtherCurrentAssetsDomain15436352026-09-30OtherNoncurrentFinancialLiabilitiesDomain15436352026-09-30OtherNoncurrentLiabilitiesDomain15436352026-09-30OtherCurrentFinancialLiabilitiesDomain15436352026-09-30OtherCurrentLiabilitiesDomain15436352026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15436352026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15436352026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15436352026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25436352026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15436352026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares543635PPLPHARMANOTLISTEDINE0DK501011PIRAMAL PHARMA LIMITEDMain BoardEquity2026-04-012027-03-312026-10-272026-10-16INRCroresQuarterlySecond quarterSingle segmentPharmaceuticals2026-10-2717:30:002026-10-2720:30:00trueCash Flow IndirectNot applicable2026-07-012026-09-30UnauditedConsolidated261706000003593000002652990000064582000003353700000-750100000714320000087630000023315000006478200000258910000006389000000638900000722000000440000007660000000-1271000000001774000005030000043790000048820000055800000-5500000493700000-550000013283900000100.040.04000.040.04Notes: <br /> <br /> 1.The unaudited consolidated financial results of the Group for the three months and six months ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026. The Statutory auditors of the Company have carried out a limited review of these results. <br /> <br /> 2.The unaudited consolidated financial results of the Group for the three months and six ended September 30, 2026 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. <br /> <br /> 3.There were no exceptional items during the quarter and six months ended 30 September 2026. Exceptional items for the quarter and year ended 31 March 2026 aggregating Rs.196.14 crore (including foreign exchnage impacts for overseas subsidiaries) comprised mainly -: <br /> (i) impairment of an intangible asset under development of Rs.175.82 crore and <br /> (ii) incremental employee benefit cost of Rs.26.94 crore arising from the Company's assessment of the impact of the Labour Codes. <br /> iii) One time settlement fees paid in quarter ended December 2025 for Rs. 14.81 crore <br /> iv) Recovery from insolvency proceedings of a vendor Rs. 21.43 crore in quarter ended June 30, 2025 <br /> <br /> 4.The group operates in only one segment and hence segment disclosure is not applicable. <br /> <br /> 5.During the quarter , the Company (Piramal Pharma Limited, PPL), completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited (“Yapan Bio”), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of Rs.76.09 crore. As a result of this transaction, PPL now owns 74% of Yapan Bio’s equity, making Yapan Bio a subsidiary of PPL. <br /> <br /> For the current quarter, as per the requirements of IND AS 103, the Group has availed the ‘measurement period’ exemption and calculated provisional goodwill, non-controlling interest, asset / liability values of Yapan Bio and remeasurement of PPL’s previously held 33.33% equity interest. These are subject to the final fair valuation report and purchase price allocation. The Group expects the final calculation to be completed by year end.2026-04-012026-09-30UnauditedConsolidated48869800000125340000050123200000137059000007556100000-36775000001389950000017570000004567000000119464000004975440000036880000003688000001375500000980000013853000000-1016500000000373000000-643500000132400000-511100000-638000000-5500000-505600000-55000001328390000010-0.48-0.4800-0.48-0.48Other Expenses (Net)6478200000Other Expenses (Net)1194640000044961400000965880000001405280000028483000000305510000010955000006267000000051960000011463000004939700000544300000011283560000032948200000261440000022537100000545020000023560000006010000003143830000081500000007253650000000185372100000132839000006813850000081422400000224700000816471000004453560000000016003000004613590000011696000003511200000013232000005213990000012117200000506500000268418000002734830000043014000004376690000072542000004897000007430000005158510000000103725000000185372100000Others519600000Others5443000000Others601000000Others8150000000Others1600300000Others1323200000Others4301400000Others72542000001757000000-2676500000-4429000000-263710000017000000-116300000-944000000276690000001555900000-147900000456700000006760000083500000-1190000000484000000037100000256500000-37600000000-64110000004605500000497430000000010652000000390910000007428000000000005920000085869000000000000000282200000000000418100000328000000-1167300000-9704700000000000122000000368480000028351000004536000000172160000000-1313300000-7108900000247900000-686100000097626000002901600000Remeasurement of Post Employment Benefit Plans-44100000-44100000Remeasurement of Post Employment Benefit Plans-141800000-141800000-11100000-35700000Deferred gains / (losses) on cash flow hedge18600000Exchange differences on translation of foreign operations506300000524900000Deferred gains / (losses) on cash flow hedge49400000Exchange differences on translation of foreign operations2444000002938000005400000055300000437900000132400000